Sfoglia per AUTORE
HUS M
Collezione AOU Città della Salute di Torino
Items : 2
Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria. in American journal of hematology / Am J Hematol. 2024 Sep;99(9):1757-1767. doi: 10.1002/ajh.27413. Epub 2024 Jun 25.
2024
AOU Città della Salute di Torino
AOU Città della Salute di Torino
Kiialainen A; Gentile B; Buatois S; Panse J; Ueda Y; Lekue CB; Lee Y; Giai V; Hus M; Bonito D; Barcellini W; Yenerel MN; Nur E; Kim JS; Clé DV; Scheinberg P; Patel H; Sreckovic S; Uguen M; Edwards J; Nagy Z; Kulasekararaj AG;
Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma. in Leukemia & lymphoma / Leuk Lymphoma. 2020 Aug;61(8):1850-1859. doi: 10.1080/10428194.2020.1747066. Epub 2020 Apr 9.
2020
AOU Città della Salute di Torino
AOU Città della Salute di Torino
Weisel K; Dimopoulos M; Moreau P; Yagci M; Larocca A; Kanate AS; Vural F; Cascavilla N; Basu S; Johnson P; Byeff P; Hus M; Rodríguez-Otero P; Muelduer E; Anttila P; Hayden PJ; Krauth MT; Lucio P; Ben-Yehuda D; Mendeleeva L; Guo S; Yu X; Grote L; Biyukov T; Dhanasiri S; Richardson P; Weisel K; Dimopoulos M; Moreau P; et alii...